Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015 (2015), Article ID 810942, 4 pages
Research Article

An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease

Department of Gastroenterology, Izmir Katip Çelebi University, İzmir Atatürk Eğitim ve Araştırma Hastanesi, Karabağlar, 35160 İzmir, Turkey

Received 19 September 2014; Accepted 2 December 2014

Academic Editor: Andrew Thillainayagam

Copyright © 2015 Zehra Betül Paköz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aim. While there are many well-defined serological markers for inflammatory bowel disease (IBD), there is limited evidence that they positively affect clinical outcomes. This study aimed to evaluate the correlation between hepcidin serum levels and disease activity in IBD. Materials and Methods. Eighty-five consecutive IBD patients were enrolled in the study. Hepcidin serum levels were assessed using an enzyme-linked immunosorbent assay (ELISA) and were compared with disease activity as well as the interleukin-6 (IL-6) and C-reactive protein (CRP) levels. Results. The mean hepcidin serum levels in Crohn’s disease (CD) patients in remission and in the active phase were and  pg/mL, respectively . The mean hepcidin serum levels in ulcerative colitis (UC) patients in remission and in the active phase were and  pg/mL, respectively . Correlation analysis between inflammatory markers and hepcidin serum levels indicated that there was no correlation between hepcidin levels and IL-6 or CRP . Conclusion. As an acute-phase protein, hepcidin seems to have a lower efficacy than other parameters in the detection of activation in IBD.